Clavis Pharma receives government grant to develop hENT1 biomarker assay for targeted therapy of AML patients
The hENT1 flow cytometry project will be a collaborative effort between scientists at Clavis Pharma and international experts in the field of cancer diagnostics.
Olav Hellebø, Clavis Pharma CEO, commented: "We are very pleased that the Research Council has recognised the importance of the development of companion diagnostics and biomarkers in cancer therapies. This grant will help us complete the final phase of our biomarker development programme".
The grant has been awarded through the BIA program that funds research-based innovation projects independent of the industrial from which they come. This broad program supports high-quality R&D projects which could deliver good business and socio-economic benefits. The grant will cover up to 35% of the total project cost and the allocation is subject to final negotiations with the Council.
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.